4-month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry

BACKGROUND: Omalizumab is licensed as add-on therapy for patients with severe allergic asthma. Response is in most studies scored by the physician’s global evaluation of treatment effectiveness (GETE). A good clinical and validated parameter for treatment response is currently missing. Also, there a...

Descripción completa

Detalles Bibliográficos
Autores principales: Snelder, S. M., Weersink, E. J. M., Braunstahl, G. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5530516/
https://www.ncbi.nlm.nih.gov/pubmed/28769983
http://dx.doi.org/10.1186/s13223-017-0206-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5530516/
https://www.ncbi.nlm.nih.gov/pubmed/28769983
http://dx.doi.org/10.1186/s13223-017-0206-9

Ejemplares similares